Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BDM E

Drug Profile

BDM E

Alternative Names: Ala-glu-asp-gly - BioDiem; Alanyl glutamyl aspartyl glycine - BioDiem; BDM-E; Epitalon - BioDiem; Epitalon tetrapeptide - BioDiem; Epithalon - BioDiem; Epithalon tetrapeptide - BioDiem

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Bioregulation and Gerontology
  • Developer BioDiem; Monash University; University of Cambridge; University of Wisconsin at Milwaukee
  • Class Eye disorder therapies; Oligopeptides; Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity Yes
  • Available For Licensing Yes - Retinitis pigmentosa

Highest Development Phases

  • Phase I/II Diabetic macular oedema
  • No development reported Age-related macular degeneration; Retinitis pigmentosa; Retinopathy of prematurity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Australia (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in Australia (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in United Kingdom (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top